Category 1: Medical CEO Patient Scripts · Episode 05

Switching from Compounded to Insurance GLP-1? The Continuity Script

Clinical Answer Capsule: When transitioning from cash-pay compounded semaglutide or tirzepatide to commercial insurance, submit prior authorization under Continuity of Care guidelines. Document baseline pre-treatment weight alongside documented clinical improvements on compounded therapy; proving established efficacy legally prevents insurers from claiming the treatment is not medically necessary.
Continuity of Care GuidelinesCompounded Semaglutide/TirzepatidePrior Authorization ApprovalSURPASS-2 ProtocolMedical Necessity Mandate
Executive Action Script
"Prior Authorization Request under Continuity of Care: Patient initiated therapy on compounded GLP-1 with verified clinical response. Discontinuation creates severe metabolic risk."

Full Video Dialogue & Clinical Context

Started on compounded semaglutide out-of-pocket and ready to make insurance pay for brand-name Wegovy or Zepbound? Do not let your provider start a brand-new authorization from scratch like a beginner. Have them submit under 'Continuity of Care' guidelines, documenting your starting weight and lab wins under compounded care. Proving the molecule already works for your body blocks insurance from claiming it's not medically necessary. Download the Compounded-to-Insurance Transition Protocol at bitchesandbesties.com/armory.

🔬 Verified Clinical Reference:
Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021; 385:503-515. PMID: 34185915
Access Study: https://pubmed.ncbi.nlm.nih.gov/34185915/
Featured Armory Instrument
Tool 01: The PA Power-Up (Prior Authorization & Appeals Arsenal)
Includes the exact Continuity of Care clinical appeal template, documentation checklist, and starting weight baseline affidavits.
Unlock Free Instrument in The Armory →